Immunoconjugates

US11413331B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Laura Codarri Deak · Schlieren, CH
• Christian Klein · Iffeldorf, DE
• Laura Lauener · Schlieren, CH
• Valeria G. Nicolini · Küsnacht (ZH), CH
• Stefan Seeber · Penzberg, DE
• Pablo Umana · Wollerau, CH
• Inja Waldhauer · Schlieren, CH

Key dates

• Filing date: Apr 2, 2018
• Grant date: Aug 16, 2022
• Expiry date: Jun 15, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.